Go Premium in Our Biggest Sale Ever

Go Ultimate 75% OFF

Lyfegen: Valuation, Funding & Investors

Aeschenvorstadt Basel, Basel-Town 4051, CHhttps://lyfegen.com/Digital Health

Lyfegen is a global leader in drug rebate management technology, providing innovative solutions to optimize pharmaceutical pricing and reimbursement processes. The company focuses on enhancing efficiency and transparency in the healthcare industry, facilitating better access to medications through its advanced platform.

Leadership & Board

Current Number of Employees: 53
Current LinkedIn Followers: 62,551

Latest Estimated Valuation

Total Amount Raised: $11M
Total Funding Rounds: 2
Latest Funding Amount: $5M
Latest Funding Round: Series A

Company Momentum

Positive

Articles Published on TipRanks2

LinkedIn Trend+0.01% followers

Workforce Trend+0.0% employees

Lyfegen LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.

Employee Trend

Lyfegen had 53 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.

53Latest Employee Count

0(0.00%)Week-Over-Week Change

Social Trend

Lyfegen had 62,551 followers as of November 9, 2026. The number of followers increased by 2 (0.00%) week-over-week.

62,551Latest Followers Count

2(0.01%)Week-Over-Week Change

Funding Round

Funding Date	Funding Round	Amount Raised	Post-Money Valuation
Aug 14, 2025	Series A	$5.00M	―
Jan 11, 2025	Series A	$5.70M	―

Investors

Investor Name	Funding Round
aMoon	Series A
TX Ventures	Series A (2)

Similar Companies

A snapshot of private companies similar to Lyfegen, helping you discover and navigate related company profiles.

Related News and Analysis

CMS Reporting Review Highlights Data Needs in Value-Based Medicaid Rebates

CMS Reporting Review Highlights Data Needs in Value-Based Medicaid Rebates

According to a recent LinkedIn post from Lyfegen, CMS estimates that states will spend about six hours annually preparing reports on value-based supplemental rebate agreements. The post highlights revised information

1w ago

Lyfegen Highlights Cross-Market Agreement Management Challenges

Lyfegen Highlights Cross-Market Agreement Management Challenges

According to a recent LinkedIn post from Lyfegen, the company’s team attended events in New York, Toronto, Lisbon, Brussels and National Harbor. The post describes recurring discussions about managing agreements,

1w ago

Medicaid Pharmacy Cost Controls Signal Opportunity for Lyfegen Analytics

Medicaid Pharmacy Cost Controls Signal Opportunity for Lyfegen Analytics

According to a recent LinkedIn post from Lyfegen, the company’s team engaged with multiple state Medicaid representatives at the National Association of Medicaid Directors Fall Conference. The post highlights that

2w ago

Lifecycle Management Focus Highlights Lyfegen’s Drug Contracting Opportunity

Lifecycle Management Focus Highlights Lyfegen’s Drug Contracting Opportunity

According to a recent LinkedIn post from Lyfegen, the company is highlighting the importance of managing drug agreements across their full lifecycle rather than focusing solely on the initial contract

3w ago

Lyfegen Highlights Focus on Canadian Market Access and Reimbursement Engagement

Lyfegen Highlights Focus on Canadian Market Access and Reimbursement Engagement

A LinkedIn post from Lyfegen describes the complexity of securing market access for pharmaceuticals in Canada, noting that a national pCPA letter of intent is followed by separate product listing

4w ago

Lyfegen Targets Opportunity in Complex Canadian Market Access Landscape

Lyfegen Targets Opportunity in Complex Canadian Market Access Landscape

According to a recent LinkedIn post from Lyfegen, the company is drawing attention to the complexity of achieving and maintaining market access for pharmaceuticals in Canada. The post notes that

4w ago

Lyfegen Targets Medicaid Drug Spend Challenges With Data-Driven Focus

Lyfegen Targets Medicaid Drug Spend Challenges With Data-Driven Focus

According to a recent LinkedIn post from Lyfegen, the company is focusing on emerging fiscal pressures in U.S. Medicaid programs, particularly around drug spending and delivery sustainability. The post points

1M ago

Lyfegen – Weekly Recap

Lyfegen – Weekly Recap

Lyfegen is a health-tech company specializing in data-driven platforms for value-based drug contracting and market access, and this weekly summary highlights its recent strategic visibility in key policy and industry

1M ago

Lyfegen Engages in European Policy Dialogue on Drug Pricing and Market Access

Lyfegen Engages in European Policy Dialogue on Drug Pricing and Market Access

According to a recent LinkedIn post from Lyfegen, the company is engaging in policy discussions on social security, market access, and drug pricing at the 5th ESIP Annual Forum in

1M ago

Lyfegen Steps Up Global Push in Value-Based Drug Contracting and Market Access

Lyfegen Steps Up Global Push in Value-Based Drug Contracting and Market Access

Lyfegen intensified its focus on value-based drug contracting and global market access this week, highlighting its role in shaping execution frameworks for complex, outcomes-linked agreements. The company’s executives are active

1M ago